AZYO Aziyo Biologics

Elutia to Participate in Chardan’s Trending Issues in Drug Development Conference Series on April 29

Elutia to Participate in Chardan’s Trending Issues in Drug Development Conference Series on April 29

SILVER SPRING, Md., April 22, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix technologies, today announced that Michelle LeRoux Williams, Ph.D., Elutia’s Chief Scientific Officer, will participate in Chardan’s Trending Issues in Drug Development Conference Series on Tuesday, April 29, 2025.

Chardan's Data & Regulatory Catalysts – Navigating an Evolving Landscape – Virtual

Format: Fireside Chat

Date and Time: Tuesday, April 29, 2025, 11:00 a.m. ET (8:00 a.m. PT)

Webcast: 

A live and archived webcast of the fireside chat will be available in the “Investors” section of the Elutia website at .

About Elutia

Elutia develops and commercializes drug-eluting biomatrix products to improve compatibility between medical devices and the patients who need them. With a growing population in need of implantable technologies, Elutia’s mission is humanizing medicine so patients can thrive without compromise. For more information, visit .

Investors:

Matt Steinberg

FINN Partners

This press release was published by a CLEAR® Verified individual.



EN
22/04/2025

Underlying

AZYOAziyo Biologics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Aziyo Biologics

 PRESS RELEASE
Free
AZYO AZIYO BIOLOGICS

Elutia to Participate in Chardan’s Trending Issues in Drug Development...

Elutia to Participate in Chardan’s Trending Issues in Drug Development Conference Series on April 29 SILVER SPRING, Md., April 22, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix technologies, today announced that Michelle LeRoux Williams, Ph.D., Elutia’s Chief Scientific Officer, will participate in Chardan’s Trending Issues in Drug Development Conference Series on Tuesday, April 29, 2025. Chardan's Data & Regulatory Catalysts – Navigating an Evolving Landscape – VirtualFormat: Fireside ChatDate and Time: Tuesday, April 29, 2025, 11:...

April 22, 2025 1 EN
 PRESS RELEASE
Free
AZYO AZIYO BIOLOGICS

Elutia Initiates EluPro™ Registry Study Designed to Generate Evidence ...

Elutia Initiates EluPro™ Registry Study Designed to Generate Evidence Supporting the Use of EluPro in Real-World Clinical Practice — Integration of clinical and patient-reported outcomes expected to further differentiate EluPro’s utility in cardiac implantable electronic device (CIED) procedures — SILVER SPRING, Md., April 21, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced the initiation of an EluPro™ clinical study designed to collect patient outcome data in real-world clinical practi...

April 21, 2025 1 EN
 PRESS RELEASE
Free
AZYO AZIYO BIOLOGICS

Elutia Confirms No Material Impact from Global Tariffs

Elutia Confirms No Material Impact from Global Tariffs SILVER SPRING, Md., April 14, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix products, today confirmed that the ongoing global tariff environment has had no material impact on its commercial or operational performance. Elutia sources, manufactures, and distributes 100% of its products within the United States, primarily from its Roswell, Georgia production facility and U.S.-based suppliers. These products include EluPro™, CanGaroo®, SimpliDerm®, and its full Cardio...

April 14, 2025 1 EN
 PRESS RELEASE
Free
AZYO AZIYO BIOLOGICS

EluPro™ Named as 2025 Edison Award Winner

EluPro™ Named as 2025 Edison Award Winner Innovative Antibiotic-Eluting BioEnvelope Designed to Protect Patients with Pacemakers and Neurostimulators Earns Bronze in Post-Surgical Recovery Solutions Category SILVER SPRING, Md., April 04, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that EluPro™, the first ever FDA-cleared antibiotic-eluting bioenvelope was honored with a 2025 Bronze Edison Award™ for its innovative approach to reducing post-surgical complications. The 2025 finalists ...

April 4, 2025 1 EN
 PRESS RELEASE
Free
AZYO AZIYO BIOLOGICS

Elutia to Participate in Upcoming Investor Conferences

Elutia to Participate in Upcoming Investor Conferences SILVER SPRING, Md., April 03, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, President and Chief Executive Officer, and Matt Ferguson, Chief Financial Officer, will participate in the following upcoming investor conferences: LD Micro 15th Annual Invitational – New York, NYFormat: Presentation and 1x1 Meetings Presentation Date and Time: Thursday, April 10, 2025, 12:30 p.m. ET (9:30 a.m. PT)Webcast: Planet Microcap Showcase – Las...

April 3, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch